Still Investors' Cup Of Tea

Snapple Beverage, whose stock short-sellers love to hate, keeps dodging brickbats. The latest is a Food & Drug Administration inquiry into whether its iced teas and fruit drinks are made from the natural ingredients it claims. When the news of the probe broke in mid-October, the stock lost two points, going to 23. (Snapple went public last December at 8.) But the FDA tells BUSINESS WEEK it has ended the investigation without taking action. A similar probe by California regulators is expected to be called off, too.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.